Mona Welschof joined Zelluna Immunotherapy in May 2017 and is responsible Zelluna’s clinical and regulatory strategy.
Mona has extensive experience in all phases of clinical drug development from early stage to registration. Prior to joining Zelluna, Mona served as Chief Clinical Officer of Vaccibody AS, where she progressed the companies first lead component, a therapeutic HPV16 DNA vaccine into the clinic, oversaw the clinical program and lead interactions with health authorities. She was Clinical Director at PCI Biotech ASA and Clinical Research Manager at Photocure ASA, where she was part of the team conducting the clinical studies and registration process of Hexvix/Cysview® the US. She also held various positions in Affitech AS, Inovio AS and Quintiles. Mona earned her PhD in the field of recombinant antibody technology from the University of Heidelberg/German Cancer Research Center in 1997.